Have a question? We’re here to help.
Stay up to date with the latest news and announcements from Excelera and the Excelera Network.
The U.S. Food and Drug Administration approved NERLYNX (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer in July 2017
Read MoreExcelera has announced the appointment of Lorrie A. Carr as its new CEO. Ms. Carr succeeds Jim Fox who retired effective April 2. She assumed her responsibilities on July 9th.
Read MoreThe Excelera Specialty Pharmacy Network, a national network of specialty pharmacies based at health systems and academic medical centers, is proud to announce sixteen pharmacists have recently earned the exclusive Certified Specialty Pharmacist (CSP) certification from the Specialty Pharmacy Certification Board (SPCB).
Read MoreExcelera announces agreement with Advent Advisory Group, one of the nation’s leading URAC-approved pharmacy measure validation vendors
Read MoreExcelera announces strategic partnership with business licensing provider LicenseLogix
Read MoreExceleraRx Corp. announced that St. John Providence has joined the Excelera national specialty pharmacy network.
Read MoreExceleraRx Corp. today announced that James M. Fox, President and Chief Executive Officer, will be retiring effective April 2, 2018
Read MoreThe Excelera Specialty Pharmacy Network, a national network of specialty pharmacies based at health systems and academic medical centers, is proud to announce seven pharmacists have recently earned the exclusive Certified Specialty Pharmacist (CSP) certification from the Specialty Pharmacy Certification Board (SPCB).
Read MoreExcelera Specialty Pharmacy Network, a national network of specialty pharmacies based at health systems and academic medical centers, is proud to announce Lana Gerzenshtein, PharmD, Jami Schell, PharmD and Zachary Russell, PharmD, have earned the exclusive Certified Specialty Pharmacist (CSP) certification from the Specialty Pharmacy Certification Board (SPCB).
Read MoreExceleraRx Corp. has joined efforts with Merck to improve patient care for approximately 3.5 million people in the United States who live with chronic HCV infection. Excelera specialty pharmacy network members will have access to Hep C products including Zepatier®.
Read More